// App-Quantinova.ai

TPS6090 : A phase 3, randomized, open-label study of epacadostat plus pembrolizumab, pembrolizumab monotherapy, and the EXTREME regimen as first-line treatment for recurrent/metastatic head and neck squamous cell carcinoma (R/M SCCHN): ECHO-304/KEYNOTE-669.

Researchers

Presenter

  • Ezra E.W. Cohen

Principal Investigators

  • Danny Rischin

  • David G. Pfister

  • Jan Baptist Vermorken

  • Yufan Zhao

  • Hema Gowda

  • Joy Yang Ge

  • Fan Jin

  • Kevin J. Harrington

Medical Centers

  • University of California, San Diego, La Jolla, CA

  • Peter MacCallum Cancer Centre, East Melbourne, Australia

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Department of oncology, Antwerp University Hospital, Edegem, Belgium

  • Incyte Corporation, Wilmington, DE

  • Merck & Co., Inc., Kenilworth, NJ

  • The Institute of Cancer Research, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom

Locations

  • United States

  • United Kingdom

  • Belgium

  • Australia

Companies

  • Incyte Corporation

  • Merck & Co., Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Indoleamine 2,3-dioxygenase 1

Drug/Treatment

  • Pembrolizumab

  • Carboplatin

  • epacadostat

  • Erbitux

  • Cisplatin

  • Adrucil injection

Outcome

  • N/A

Study Design

  • Randomized

  • Open Label

Phase

  • III

Study Id's

  • NCT03358472

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved